JV孵化,如何养成2025年港股创新药第一股 ? | 专访维梧资本管理合伙人付山

医药魔方Invest
May 12

“七八年前,我们选择JV(joint venture)孵化模式成立维升药业。”维梧资本管理合伙人付山说到,“今天看,这条路是适合维升药业发展的,优秀的产品需要杰出的团队花时间去专注耕耘,维升沉淀出了成果。”3月21日,维升药业正式在港交所上市,引入的基石投资者阵容豪华,除了孵化维升药业的维梧资本再度加仓,苏州工业园区产业投资基金也重磅加持,安科生物和药明生物两家产业资本入局。不仅如此,维升药业此次...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10